Crédit Agricole Financement de l'Habitat SFH (the “Issuer”) announces today the early repurchase (the « Repurchase ») with effect on December 16, 2025 (the « Repurchase Date ») of all of its outstanding EUR 3,250,000,000 “obligations de financement de l'habitat” Fixed Rate Notes issued on July 28, 2023 and due June 15, 2026 (ISIN: FR001400JM09) (the « Notes ») pursuant to the Terms and Conditions of the Notes (the “Terms and Conditions”) included in the prospectus dated July 20, 2023, which was granted the ...

SkiStar AB will publish the Interim Report for the period 1 September 2025 – 30 November 2025 on Thursday 18 December 2025 at 07.00 a.m. CET. In connection with the report SkiStar will organize a conference call with web presentation. CEO Stefan Sjöstrand and CFO Sara J Uggelberg will present and comment on the report. After the presentation there will be time for questions, both by phone and by chat in the web presentation. The presentation will be held in English. Time for conference call and web presenta ...

Core Insights - Wolters Kluwer has repurchased 209,603 ordinary shares for €18.7 million at an average price of €89.33 during the period from December 4 to December 10, 2025 [1] - The share buyback program, announced on November 5, 2025, aims to repurchase shares up to €200 million from November 6, 2025, to February 23, 2026 [2] - Cumulatively, 8,060,900 shares have been repurchased in 2025, totaling €1,054.9 million at an average price of €130.86 [2] Share Buyback Program Details - The company has engaged a third party to execute the €200 million buyback program within legal limits [2] - Shares repurchased will be held as treasury shares and used for capital reduction through share cancellation [3] Company Overview - Wolters Kluwer is a global leader in professional information solutions, software, and services across various sectors including healthcare, tax, accounting, and legal [4] - The company reported annual revenues of €5.9 billion in 2024 and operates in over 180 countries with approximately 21,900 employees [5] - Wolters Kluwer shares are listed on Euronext Amsterdam and included in major indices such as AEX and Euro Stoxx 50 [6]

Core Points - The European Investment Bank (EIB) has announced a funding programme of EUR 60 billion for the year 2026 [1] - The EIB Board of Directors approved a borrowing authorization of up to EUR 65 billion, providing flexibility for potential increases in funding [1] - In 2025, the EIB successfully raised EUR 63.9 billion [1] Company Background - The EIB is the long-term financing institution of the European Union, owned by its Member States [1] - The institution aims to make finance available for sound investments to support EU policy goals [1] - The EIB's strong credit standing is supported by exceptional asset quality, a robust capital base, liquidity, firm shareholder support, conservative risk management, and a sound funding strategy [1]

Core Insights - Sino Bioking (Tianjin) Biological Pharmaceutical Co., Ltd. is set to launch its recombinant feline interferon product, a Class II new veterinary drug, marking a significant advancement in China's veterinary drug market [1] - The Beijing-Tianjin Zhongguancun Tech Town is emerging as a key hub for biomedical innovation, supporting the national strategy for coordinated development in the Beijing-Tianjin-Hebei region [2][7] Company Developments - Sino Bioking has expanded its R&D and quality control center from 200 to 2,000 square meters and completed a third production line in 2025 [5] - The company has secured over 20 patents and is on a fast track for product development, supported by equity financing from a joint initiative of local financial services [6] Strategic Location and Support - The selection of Beijing-Tianjin Zhongguancun Tech Town as the manufacturing base was influenced by its strategic location and robust support policies [3] - The park's "end-to-end dedicated services" and tailored approval processes have significantly streamlined Sino Bioking's project timeline [4] Future Outlook - The tech town aims to attract more biomedical enterprises and enhance its role in regional industrial upgrading, contributing to China's biopharmaceutical innovation landscape [9] - The local government emphasizes the importance of talent cultivation and optimizing the business environment to foster a thriving ecosystem for biomedical startups [8]

Core Points - CBL International Limited's Chairman and CEO, Dr. Teck Lim Chia, has been awarded in the Directors of the Year Awards by the Hong Kong Institute of Directors for his contributions to corporate governance and sustainable value creation [1][2][3] Company Overview - CBL International Limited (NASDAQ: BANL) serves as the listing vehicle for the Banle Group, a marine fuel logistics company established in 2015, focusing on vessel refueling solutions [9] - The company operates in 65 major ports across regions including Asia Pacific, Europe, and Central America, promoting the use of sustainable fuels and holding ISCC EU and ISCC Plus certifications [9] Leadership Recognition - The award recognizes Dr. Chia's excellence in strategic oversight, ethical leadership, and long-term sustainable performance during his tenure at CBL International [2][3] - Under Dr. Chia's leadership, CBL has enhanced its investor relations, improved ESG disclosures, and maintained compliance with international standards [3][5] Company Values - Dr. Chia emphasized that governance is integral to decision-making at CBL, reflecting a commitment to integrity, innovation, and responsible growth [4] - The Board of CBL International expressed pride in Dr. Chia's leadership, highlighting his ability to balance strategic ambition with disciplined oversight [5]

Core Insights - Heartflow, Inc. announced significant findings from the FISH&CHIPS study, demonstrating that its FFRCT Analysis improves diagnostic decision-making and predicts cardiovascular events while providing substantial cost savings for healthcare systems [1][2][4] Group 1: Clinical Value - The FISH&CHIPS study, involving over 90,000 patients, is the largest FFRCT study to date, providing strong real-world evidence of the clinical benefits of Heartflow's technology [1][7] - Heartflow FFRCT Analysis predicts individual cardiovascular outcomes, including myocardial infarction (MI) and cardiovascular mortality, with lower FFRCT values correlating to higher risks of adverse events [3][5] - The technology enables clinicians to tailor care more precisely, improving patient outcomes and reducing costs [4][5] Group 2: Economic Impact - The introduction of Heartflow FFRCT Analysis into the NHS led to fewer avoidable tests and lower costs for both inpatient and outpatient care, resulting in significant savings for hospitals and patients [2][5] - The analysis indicated a per-patient cost saving of £1,042 GBP ($1,394 USD) over two years, suggesting potential annual savings of £25 million GBP ($33.45 million USD) for the health system [5] - Cost savings were observed from the first year and continued to persist in lifetime modeling, highlighting the economic viability of the technology [5] Group 3: Technological Advancements - Heartflow's platform integrates various analyses, including RoadMap™ Analysis and Plaque Analysis, enhancing the accuracy of CAD assessments [4][8] - The technology has been adopted by over 1,400 institutions globally, supported by extensive clinical validation and a large dataset of coronary imaging [8][9] - Heartflow's AI-driven solutions have been validated in over 100 studies, demonstrating high acceptance rates and reproducibility in clinical practice [8]

Core Insights - Advantest Corporation has launched the T2000 AiR2X, a next-generation air-cooled test system designed to meet the increasing demand for compact and cost-efficient testers in high-mix, low-volume production environments [1][2] - The T2000 AiR2X offers double the test resources compared to its predecessor, the T2000 AiR, while maintaining low power and air-cooling requirements [1][2] - The new system is fully compatible with the existing T2000 test system, facilitating seamless migration from older models [1][2] Market Demand and Positioning - The T2000 AiR2X addresses the need for end-of-life support for legacy systems like the T6500 and T7700 series, as well as ongoing replacement needs for compact air-cooled testers [2] - With a significant number of air-cooled SoC test systems in operation globally, Advantest is well-positioned to meet sustained demand in this growing market [2] Product Features and Benefits - The T2000 AiR2X supports up to 12 measurement modules, including functional/SCAN tests and high-precision DC testing up to 320V, which enhances its versatility [3][4] - The system's multisite controller function significantly reduces test time during volume production, improving deployment efficiency [3] - Incorporating the T2000 RECT550 performance board, the T2000 AiR2X allows for a wide range of configurations and utilizes the same program environment as the T2000, streamlining platform migration and implementation [4] Initial Evaluations and Applications - Initial evaluations of the T2000 AiR2X confirm its broad application coverage across various sectors, including industrial MCUs, consumer ASICs, automotive battery-monitoring ICs, and power analog applications [5] - The system is set to enter general availability later this month, indicating a timely introduction to the market [5] Company Overview - Advantest Corporation is a leading manufacturer of automatic test and measurement equipment for semiconductor design and production, with applications in 5G communications, IoT, autonomous vehicles, and high-performance computing [6] - Founded in Tokyo in 1954, Advantest has a global presence and is committed to sustainable practices and social responsibility [6]

Core Points - Shell plc announces significant changes to its Board and Committees, including the non-re-election of two Non-Executive Directors, Catherine Hughes and Neil Carson, at the 2026 AGM [1][4] - New appointments include Holly Koeppel and Clare Scherrer as Non-Executive Directors, effective January 1, 2026, with roles in various committees [2][5] - Sir Andrew Mackenzie will take on the role of Chair of the Sustainability Committee following the 2026 AGM [7] Director Changes - Catherine Hughes will not stand for re-election after nine years of service, and Neil Carson will also not seek re-election after seven years [1] - Both directors have made significant contributions during their tenures, with Hughes leading the Sustainability Committee and Carson chairing the Remuneration Committee [3][4] New Non-Executive Directors - Holly Koeppel brings extensive international energy industry experience and will join the Audit and Risk Committee and the Sustainability Committee [2][8] - Clare Scherrer has a background in capital-intensive global industrial companies and will serve on the Audit and Risk Committee and the Remuneration Committee [2][8] Committee Membership Changes - Following the 2026 AGM, the Audit and Risk Committee will include new members Koeppel and Scherrer, while Mackenzie will chair the Sustainability Committee [9]

Company Overview - DFDS operates a transport network in and around Europe with an annual revenue of DKK 30 billion and employs 16,500 full-time staff [2] - The company provides services for moving goods in trailers via ferry, road, and rail, along with complementary transport and logistics solutions [2] - DFDS also facilitates the movement of car and foot passengers on short sea and overnight ferry routes [2] - Founded in 1866, DFDS is headquartered and listed in Copenhagen [2] Financial Calendar for 2026 - The deadline for submission of proposals to the Annual General Meeting (AGM) is set for 11 February 2026 [1] - The annual report for 2025 and Q4 review will be released on 19 February 2026 [1] - The AGM is scheduled for 25 March 2026 [1] - The Q1 report for 2026 will be published on 5 May 2026 [1] - The Q2 report for 2026 is expected on 14 August 2026 [1] - The Q3 report for 2026 will be available on 5 November 2026 [1] Monthly Ferry Volume Updates for 2026 - Monthly ferry volume updates will be released on the following dates in 2026: - 13 January - 12 February - 12 March - 14 April - 12 May - 11 June - 10 July - 14 August (7:30 am CET) - 11 September - 13 October - 12 November - 11 December [1]